- Home
- RDIB vs LUCD Comparison
RDIB vs LUCD Comparison
Compare RDIB & LUCD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | RDIB | LUCD |
|---|---|---|
| Founded | 1937 | 2018 |
| Country | United States | United States |
| Employees | 2005 | N/A |
| Industry | Movies/Entertainment | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 204.7M | 174.4M |
| IPO Year | N/A | 2021 |
Fundamental Metrics
Financial Performance| Metric | RDIB | LUCD |
|---|---|---|
| Price | $8.99 | $0.95 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $4.13 |
| AVG Volume (30 Days) | 12.7K | ★ 1.5M |
| Earning Date | 05-14-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 16.67 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $4,346,000.00 |
| Revenue This Year | $16.25 | $115.58 |
| Revenue Next Year | $4.04 | $130.54 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 79.00 |
| 52 Week Low | $8.01 | $0.86 |
| 52 Week High | $17.40 | $1.63 |
Technical Indicators
Market Signals| Indicator | RDIB | LUCD |
|---|---|---|
| Relative Strength Index (RSI) | 50.67 | 48.06 |
| Support Level | $8.49 | $0.93 |
| Resistance Level | $10.50 | $1.11 |
| Average True Range (ATR) | 0.50 | 0.05 |
| MACD | 0.01 | 0.01 |
| Stochastic Oscillator | 44.75 | 51.59 |
Price Performance
Historical ComparisonAbout RDIB Reading International Inc Class B
Reading International Inc is a diversified company, engaged in the development, ownership, and operation of multiplex cinemas and retail and commercial real estate in the United States, Australia, and New Zealand. It operates through two segments: the Cinema segment includes Reading Cinemas, Angelika Film Center, Consolidated Theatres, and City Cinemas; the Real Estate segment includes real estate development and the rental or licensing of retail, commercial and live theater assets.
About LUCD Lucid Diagnostics Inc.
Lucid Diagnostics Inc is a commercial-stage medical diagnostics technology company focused on the millions of patients with gastroesophageal reflux disease (GERD), also known as chronic heartburn, acid reflux, or simply reflux, who are at risk of developing esophageal precancer and cancer, specifically lethal esophageal adenocarcinoma. Its products include EsoCheck and EsoGuard.